NUNHEAD PHARMACY LTD 31/12/2024 iXBRL

Company registration number: 13819317

NUNHEAD PHARMACY LTD

Unaudited filleted financial statements

31 December 2024

NUNHEAD PHARMACY LTD

Contents

Directors and other information

Accountants report

Statement of financial position

Statement of changes in equity

Notes to the financial statements

NUNHEAD PHARMACY LTD

Directors and other information


	Director	Mr R G Patel


	Company number	13819317


	Registered office	298
		Lewisham High Street
		London
		England
		SE13 6JZ


	Accountants	Accounts Tax Solutions Limited
		3, Grove Street
		Wilmslow
		Cheshire
		SK9 1DU

NUNHEAD PHARMACY LTD

Report to the director on the preparation of the

unaudited statutory financial statements of NUNHEAD PHARMACY LTD

Year ended 31 December 2024

As described on the statement of financial position, the director of the company is responsible for the preparation of the financial statements for the year ended 31 December 2024 which comprise the statement of financial position, statement of changes in equity and related notes.

You consider that the company is exempt from an audit under the Companies Act 2006. In accordance with your instructions we have compiled these unaudited financial statements in order to assist you to fulfil your statutory responsibilities, from the accounting records and from information and explanations supplied to us.

Accounts Tax Solutions Limited

3, Grove Street

Wilmslow

Cheshire

SK9 1DU

26 September 2025

NUNHEAD PHARMACY LTD

Statement of financial position

31 December 2024

		2024		2023
	Note	£	£	£	£

Fixed assets
Intangible assets	5	127,230		134,714
Tangible assets	6	28,522		34,715
		_______		_______
			155,752		169,429

Current assets
Stocks		57,673		53,926
Debtors	7	96,755		98,588
Cash at bank and in hand		148,695		101,760
		_______		_______
		303,123		254,274
Creditors: amounts falling due
within one year	8	( 124,211)		( 132,046)
		_______		_______
Net current assets			178,912		122,228
			_______		_______
Total assets less current liabilities			334,664		291,657

			_______		_______
Net assets			334,664		291,657
			_______		_______

Capital and reserves
Called up share capital			1		1
Profit and loss account			334,663		291,656
			_______		_______
Shareholder funds			334,664		291,657
			_______		_______

For the year ending 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

- The member has not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476;

- The director acknowledges their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

In accordance with section 444 of the Companies Act 2006, the statement of comprehensive income has not been delivered.

These financial statements were approved by the board of directors and authorised for issue on 26 September 2025 , and are signed on behalf of the board by:

Mr R G Patel

Director

Company registration number: 13819317

NUNHEAD PHARMACY LTD

Statement of changes in equity

Year ended 31 December 2024

	Called up share capital	Profit and loss account	Total
	£	£	£


At 1 January 2023	1	297,066	297,067

Profit/(loss) for the year		( 5,410)	( 5,410)
	_______	_______	_______
Total comprehensive income for the year	-	( 5,410)	( 5,410)

	_______	_______	_______
At 31 December 2023 and 1 January 2024	1	291,656	291,657

Profit/(loss) for the year		43,007	43,007
	_______	_______	_______
Total comprehensive income for the year	-	43,007	43,007

	_______	_______	_______
At 31 December 2024	1	334,663	334,664
	_______	_______	_______

NUNHEAD PHARMACY LTD

Notes to the financial statements

Year ended 31 December 2024

1. General information

The company is a private company limited by shares, registered in England and Wales. The address of the registered office is Nunhead Pharmacy Ltd, 298, Lewisham High Street, London, England, SE13 6JZ.

2. Statement of compliance

These financial statements have been prepared in compliance with the provisions of FRS 102, Section 1A, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

3. Accounting policies

Basis of preparation

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.

The financial statements are prepared in sterling, which is the functional currency of the entity.

Turnover

Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

Taxation

The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.

Goodwill

Goodwill arises on business acquisitions and represents the excess of the cost of the acquisition over the company's interest in the net amount of the identifiable assets, liabilities and contingent liabilities of the acquired business. Goodwill is measured at cost less accumulated amortisation and accumulated impairment losses. It is amortised on a straight line basis over its useful life. Where a reliable estimate of the useful life of goodwill or intangible assets cannot be made, the life is presumed not to exceed ten years.

Amortisation

Amortisation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful life of that asset as follows:


Goodwill	-	5 %	straight line

If there is an indication that there has been a significant change in amortisation rate, useful life or residual value of an intangible asset, the amortisation is revised prospectively to reflect the new estimates.

Tangible assets

tangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in capital and reserves, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in capital and reserves in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in capital and reserves in respect of that asset, the excess shall be recognised in profit or loss.

Depreciation

Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:


Plant and machinery	-	20 %	reducing balance
Fittings fixtures and equipment	-	25 %	reducing balance

If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates.

Stocks

Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost includes all costs of purchase, costs of conversion and other costs incurred in bringing the stocks to their present location and condition.

4. Staff costs

The average number of persons employed by the company during the year amounted to 9 (2023: 8 ).

The aggregate payroll costs incurred during the year were:

	2024	2023
	£	£
Wages and salaries	241,586	199,593
Social security costs	11,206	11,338
Other pension costs	602	1,691
	_______	_______
	253,394	212,622
	_______	_______

5. Intangible assets

	Goodwill	Total
	£	£
Cost
At 1 January 2024 and 31 December 2024	600,000	600,000
	_______	_______
Amortisation
At 1 January 2024	465,286	465,286
Charge for the year	7,484	7,484
	_______	_______
At 31 December 2024	472,770	472,770
	_______	_______
Carrying amount
At 31 December 2024	127,230	127,230
	_______	_______
At 31 December 2023	134,714	134,714
	_______	_______

6. Tangible assets

	Plant and machinery	Fixtures, fittings and equipment	Total
	£	£	£
Cost
At 1 January 2024	50,000	3,681	53,681
Additions	-	1,181	1,181
	_______	_______	_______
At 31 December 2024	50,000	4,862	54,862
	_______	_______	_______
Depreciation
At 1 January 2024	18,000	966	18,966
Charge for the year	6,400	974	7,374
	_______	_______	_______
At 31 December 2024	24,400	1,940	26,340
	_______	_______	_______
Carrying amount
At 31 December 2024	25,600	2,922	28,522
	_______	_______	_______
At 31 December 2023	32,000	2,715	34,715
	_______	_______	_______

7. Debtors

	2024	2023
	£	£
Trade debtors	3,770	3,770
Other debtors	92,985	94,818
	_______	_______
	96,755	98,588
	_______	_______

8. Creditors: amounts falling due within one year

	2024	2023
	£	£
Trade creditors	103,444	123,205
Corporation tax	5,543	-
Social security and other taxes	4,518	4,634
Other creditors	10,706	4,207
	_______	_______
	124,211	132,046
	_______	_______